Journal Article

Amphotericin B and Itraconazole for Treatment of Disseminated <i>Penicillium marneffei</i> Infection in Human Immunodeficiency Virus-Infected Patients

Thira Sirisanthana, Khuanchai Supparatpinyo, Joseph Perriens and Kenrad E. Nelson

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 26, issue 5, pages 1107-1110
Published in print May 1998 | ISSN: 1058-4838
Published online May 1998 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/520280
Amphotericin B and Itraconazole for Treatment of Disseminated Penicillium marneffei Infection in Human Immunodeficiency Virus-Infected Patients

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Disseminated infection with Penicillium marneffei is common in patients infected with human immunodeficiency virus (HIV) in Southeast Asia. Treatment with amphotericin B alone is effective but requires a prolonged hospital stay. We conducted an open-label nonrandomized study to evaluate the efficacy and safety of treatment with amphotericin B at a dosage of 0.6 mg/(kg · d) intraveneously for 2 weeks, followed by a 400-mg/d dosage of oral itraconazole for 10 weeks. Of the 74 HIV-infected patients we studied who had disseminated P. marneffei infection, diagnosed by positive fungal culture and clinical evidence of infection, 72 (97.3%) responded to the treatment. There were no serious adverse drug effects. It was concluded that the regimen was effective and safe for treatment of disseminated P. marneffei infection in HIV-infected patients.

Journal Article.  0 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.